Preferred therapies for severe COVID-19/ Cytokine Release Syndrome	% of Respondents (N=14)	Available Clinical Trials	% of Respondents (N=14)
Anti-virals (Remdesivir, Lopinavir/Ritonavir, Ribavirin, Arbidol, Favipiravir)	46.2%	Remdesivir	72.7%
Hydroxychloroquine or chloroquine	30.8%	Lopinvir/ritonavir	36.4%
Anti- IL6 (Tocilizumab)	15.4%	Hydroxychloroquine or chloroquine	45.5%
Corticosteroids	7.7%	Convalescent plasma	36.4%
Intravenous immunoglobulins (IVIg)	7.7%	Anti-IL6 (Tocilizumab)	27.3%
		Corticosteroids	27.3%
		Favipiravir	18.2%
		Interferons	9.1%
		Ribavarin	9.1%